Analysts expect Soleno Therapeutics Inc (NASDAQ:SLNO) to report earnings of ($0.17) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Soleno Therapeutics’ earnings. Soleno Therapeutics posted earnings per share of ($0.11) in the same quarter last year, which suggests a negative year over year growth rate of 54.5%. The business is scheduled to issue its next earnings results on Thursday, November 21st.
According to Zacks, analysts expect that Soleno Therapeutics will report full year earnings of ($0.85) per share for the current year. For the next year, analysts expect that the business will post earnings of ($0.84) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Soleno Therapeutics.
Soleno Therapeutics (NASDAQ:SLNO) last posted its earnings results on Wednesday, August 7th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.13).
Several analysts have commented on the stock. Zacks Investment Research upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research note on Saturday, November 2nd. ValuEngine upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th.
NASDAQ:SLNO traded down $0.01 during trading hours on Tuesday, reaching $1.41. The company had a trading volume of 37,400 shares, compared to its average volume of 496,813. The firm has a market cap of $47.69 million, a price-to-earnings ratio of -2.17 and a beta of 2.31. The firm’s 50 day moving average price is $1.59 and its 200-day moving average price is $2.10. Soleno Therapeutics has a 52 week low of $1.11 and a 52 week high of $5.07.
In other Soleno Therapeutics news, major shareholder Ventures Fund V. L.P. Vivo sold 334,417 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $1.50, for a total value of $501,625.50. Also, Director Andrew Sinclair purchased 2,300,000 shares of the firm’s stock in a transaction on Friday, October 25th. The stock was bought at an average price of $1.53 per share, for a total transaction of $3,519,000.00. 26.56% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in the business. Lindbrook Capital LLC purchased a new stake in Soleno Therapeutics in the 2nd quarter worth $30,000. Bank of New York Mellon Corp purchased a new stake in shares of Soleno Therapeutics during the 2nd quarter valued at about $49,000. Trellus Management Company LLC raised its position in shares of Soleno Therapeutics by 11.4% during the 2nd quarter. Trellus Management Company LLC now owns 268,000 shares of the company’s stock valued at $750,000 after buying an additional 27,355 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Soleno Therapeutics by 14.1% during the 2nd quarter. Vanguard Group Inc. now owns 243,879 shares of the company’s stock valued at $683,000 after buying an additional 30,092 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of Soleno Therapeutics by 86.0% during the 2nd quarter. BlackRock Inc. now owns 72,061 shares of the company’s stock valued at $202,000 after buying an additional 33,319 shares in the last quarter. Institutional investors and hedge funds own 46.05% of the company’s stock.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017.
Further Reading: How Investors Use a Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.